[Position of the Japanese Subgroup Data from Global Trial in Advanced Gastric Cancer]

Area of Science:

• Oncology
• Clinical Pharmacology

Background:

• Global drug development aims for early approval, necessitating regional efficacy assessments.
• Japanese regulatory approval requires demonstrating effectiveness within Japan's specific medical context.
• Gastric cancer treatment outcomes and survival rates show significant disparities between Japan and other regions.

Purpose of the Study:

• To highlight the importance of Japanese subgroup data in global cancer chemotherapy trials.
• To address the unique challenges in interpreting Japanese subgroup data for gastric cancer.

Main Methods:

• Analysis of Japanese patient subgroup data within global clinical trials.
• Consideration of regional differences in survival times and surgical outcomes.
• Evaluation of factors influencing data robustness, including patient numbers and censoring rates.

Main Results:

• Japanese subgroup data is critical for drug approval and reimbursement in Japan.
• Gastric cancer patient characteristics in Japan present unique analytical challenges.
• Small sample sizes and high censoring rates in the Japanese subgroup require cautious interpretation.

Conclusions:

• Robust Japanese domestic data is essential for new cancer chemotherapy agents.
• Interpreting Japanese subgroup data necessitates careful consideration of its specific characteristics.
• Addressing regional variations is key to successful global drug development and approval.